Skip to main content
Journal of Diabetes Research logoLink to Journal of Diabetes Research
. 2020 Jul 20;2020:4376251. doi: 10.1155/2020/4376251

Suboptimal Blood Pressure Control, Associated Factors, and Choice of Antihypertensive Drugs among Type 2 Diabetic Patients at KCMC, Tanzania

Gabriel W Mbwete 1,, Kajiru G Kilonzo 1,2, Elichilia R Shao 1,2, Nyasatu G Chamba 1,2
PMCID: PMC7391100  PMID: 32775461

Abstract

Background

Hypertension (HTN) can be present in up to two-thirds of patients living with diabetes mellitus (DM). It is a risk factor for the development of diabetes as well as complications like coronary artery disease (CAD), nephropathy, retinopathy, and neuropathy. Hypertension is treatable, and the degree to which it is controlled determines the risk of development of cardiovascular diseases and other complications in a given individual patient. Even though antihypertensive drugs are available and issued to hypertensive diabetic patients, the rate of control of HTN is often inadequate. The aim of this study was to assess the prevalence of suboptimal blood pressure (BP) control, its associated factors, and the choice of antihypertensive drugs among type 2 DM patients at Kilimanjaro Christian Medical Centre (KCMC).

Methods

A hospital-based cross-sectional study was conducted at the KCMC diabetes clinic from October 2018 to March 2019 among type 2 DM patients with HTN based on the inclusion criteria. Data were collected using structured questionnaires, and written informed consent was obtained. Suboptimal BP was defined as BP levels ≥ 140/90 mmHg according to the American Diabetes Association guideline published in 2018. Data analysis was done using the Statistical Package for the Social Sciences (SPSS) version 25. Chi-square analysis was done to identify the independent predictors of BP control, and a p value of <0.05 was considered to be statistically significant.

Results

The data of 161 participants was analysed; the mean age was 63.9 ± 20.2 years, with the majority being females (67.1%). Despite all participants being on different classes of antihypertensives, 57.8% had suboptimal BP control. Among the participants with good BP control, 52.7% were on angiotensin-converting enzyme inhibitors (ACE-I). Poor diabetes control was observed in 50.1% participants as indicated by elevated glycated haemoglobin.

Conclusion

This study demonstrated that BP control in type 2 DM patients was suboptimal in more than half of the participants. The study showed that the use of ACE-I or angiotensin II receptor blockers (ARBs) in the majority of DM patients has a good impact in the control of blood pressure. The early initiation of ACE-I or ARBs among the diabetic patients will improve the optimal BP control.

1. Introduction

Diabetes mellitus (DM), more simply called diabetes, is a group of metabolic diseases characterised by hyperglycaemia resulting from defects in insulin secretion, insulin action, or both.

According to the International Diabetes Federation (IDF) report published in 2017, DM is estimated to affect over 425 million people or 8.8% of adults aged 20-79 years worldwide and expected to rise to 629 million by the year 2045. Africa is estimated to have 16 million people living with DM, which is predicted to increase to 41 million people by the year 2045. Approximately 87% to 91% of all people with DM have type 2 DM especially in the high-income countries. [1]

Hypertension (HTN) in patients living with DM is contributed by insulin resistance, obesity, and inactivity [2]. Studies have shown that 40% of individuals with type 2 DM already have HTN at the time of diagnosis and the remaining percentage develop hypertension later in life [3]. Both HTN and DM are noncommunicable diseases (NCDs) which are extremely common and frequently coexist. They are major contributors to the development and progression of macrovascular complications such as coronary artery diseases, stroke, and peripheral artery diseases and microvascular complications which include nephropathy, neuropathy, and retinopathy in people with DM compared to the general population [4].

The growing burden of DM and HTN globally is considered to be a major medical and public health problem associated with increased morbidity and mortality. Nonoptimal BP control is the leading cause of deaths globally responsible for 7 million deaths annually of which most are from low- and middle-income countries (LMIC) [5].

HTN is a major modifiable risk factor for cardiovascular diseases (CVDs) including heart failure and myocardial infarction, estimated to cause 65% deaths globally [6]. Lowering BP is particularly beneficial in diabetic patients; however, there is no specific level of lowering BP when cardiovascular and renal complications start to occur; thus, the definition of HTN is arbitrary and needed for practical reasons in patient assessment and treatment. The knowledge that reduction of BP in severe HTN reduces complications implies long-term supervision of therapy for many hypertensive patients so as to ensure adequate control of BP in order to prevent the complications of a poorly controlled BP [7]. There is no threshold for the risk of CVD, but rather a continuous decrease in risk as blood pressure is reduced.

The Appropriate BP Control in DM (ABCD) study, the United Kingdom Prospective Diabetes Study (UKPDS), and the Hypertension Optimal Treatment (HOT) trial showed a consistent benefit on cardiovascular events or mortality when BP is reduced. The number of patients with diabetes in Tanzania is increasing. Prevalence of HTN among patients with diabetes is equally high [8]. Furthermore, diabetes patients with poorly controlled HTN have a greater risk of delayed onset complications and poor prognosis of both conditions.

The degree of control of HTN in both rural and urban areas of Tanzania is not well established; therefore, effective BP control in DM patients is an important goal that demands special attention. The American Diabetes Association (ADA) guidelines published in 2018 recommends blood pressure targets of <140/90 mmHg in patients with diabetes [9]. This study was aimed at determining the prevalence of suboptimal BP control among diabetic patients and the associated risk factors as well as at evaluating appropriate antihypertensive medication to manage HTN in diabetic patients.

2. Methods

A hospital-based cross-sectional analytical study was conducted at the Kilimanjaro Christian Medical Centre (KCMC) diabetes clinic from October 2018 to March 2019 among type 2 DM patients with HTN. KCMC is a consultant referral hospital in north-eastern Tanzania. It caters to a wide population estimated to be over 15 million in the northern part of the country. The diabetes clinic is run once a week with an average of 100 patients on each clinic day.

Patients with type 2 DM above 18 years old with established clinical diagnosis of hypertension and on regular medications were considered eligible and enrolled consecutively until the desired sample size of 161 was attained. The diagnosis of HTN was defined as BP ≥ 140/90 mmHg based on the ADA guideline published in 2018 [9] and the JNC 7 guideline which categorised HTN as stage 1 BP 140/90-159/99 mmHg and stage 2 BP ≥ 160/100 mmHg; those participants who were on antihypertensive medications according to the patients' files were also considered hypertensive. Patients who were too sick to provide written informed consent and pregnant women were excluded from the study.

2.1. Data Collection

A face-to-face interview was conducted, after obtaining written informed consent. A structured questionnaire was used to collect the patients' sociodemographic characteristics and the duration of HTN and DM. The history of drug compliance and regular clinic attendance was obtained from the patients' files, and the attendance of three months consecutively was regarded as regular. Physical activity was assessed using the International Physical Activity Questionnaires (IPAQ). This is the validated tool for self-reported measure of physical activity. After 5 minutes of rest, the BP was measured using the Spengler sphygmomanometer; then, a second reading was taken after 5 minutes of the first reading, and the third BP reading was obtained from the patients' last medical visit records, and thus, the overall average BP was obtained. The drug medications were self-reported using the single item past 7 days by [10]. Suboptimal BP was defined as BP levels ≥ 140/90 mmHg according to the American Diabetes Association guideline published in 2018 for the management of hypertension in patients with DM [9]. The body mass index (BMI) for participants was calculated by obtaining the weight in kilograms (kg) and height in meter squared (m2). Random blood glucose (RBG) was measured using a standardized Gluco Plus machine (Glucometer Type 25 KB JPG) capillary finger prick method, and further venous blood samples were drawn for serum creatinine, serum urea and fasting total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) and for glycated haemoglobin (HBA1C), and lastly midstream urine for protein was taken.

2.2. Data Management and Analysis

Data analysis was done using the Statistical Package for the Social Sciences (SPSS) version 25.

Categorical variables were expressed as proportions and percentages while continuous variables were expressed as means ± standard deviation. Comparison between categorical variables was done by the use of the chi-square test, while that of numerical variables was done by the use of analysis of variance; multivariates were used to assess the strength of association between the independent and dependent variables in the study, and a p value of <0.05 was considered to be statistically significant. We categorised BP as normal when it was <140/90 mmHg, stage 1 HTN when it was 140/90 mmHg to 159/99mmHg, and stage 2 HTN when it was ≥160/100 mmHg.

3. Results

The data of 161 participants were analysed in this study. The majority of the study participants were females 108 (67.1%), and the mean age of the participants was 63.9 ± 20.4 years; the majority of them 124 (77%) were aged between 50 and 75 years. The highest level of education attained by most of the participants was primary level which accounted for 59.6%, and 76 (47.2%) of the respondents were either peasants or small-scale farmers; the majority of them were either current drinkers or those who used to take alcohol, accounting for 67.8%, and cigarette smoking was observed in 14 (8.7%) of the respondents. Among the respondents, 67.7% had taken initiative measures of reducing salt intake in their meals. Two-thirds of the participants were covered by the National Health Insurance Fund (NHIF) in Tanzania. Other subscribers from different insurance companies were not considered because they were temporarily suspended by the hospital management during the time of the study (see Table 1).

Table 1.

Sociodemographic characteristics of the participants (n = 161).

Variables N %
Sex
 Male 53 32.9
 Female 108 67.1
Age
 <50 12 7.5
 50-75 124 77
 75+ 25 15.5
Level of education
 None 3 1.9
 Primary 96 59.6
 Secondary+ 62 38.5
Occupation
 Employed 37 23
 Peasant/farmer 76 47.2
 Retired 48 29.8
Salt reduction in food
 No 52 32.3
 Yes 109 67.7
Smoker
 No 147 91.3
 Yes 14 8.7
Drink alcohol
 No 52 32.3
 Yes 109 67.7
Who pays for the medication
 NHIF 142 88.2
 Cash 19 11.8

In the medical and laboratory characteristics shown in Table 2, the family history of hypertension among the participants was 30.4% and 37.3% have been hypertensive for more than 5 years. Physical inactivity was reported in 6.2% of the participants, and 83 (51.6%) were overweight. The total serum cholesterol was normal in 63.2% with 51.5% of triglycerides. Urine for protein was negative in 80.8%, and normal serum creatinine was reported in 128 (79.5%) of the participants. 50.3% of the participants had uncontrolled blood sugar for the past three months prior to this study as demonstrated by the HBA1C as shown in Table 2.

Table 2.

Clinical and laboratory characteristics of the participants (n = 161).

Variables N %
Duration since hypertension diagnosis
 <5 years 63 39.1
 5-10 years 60 37.3
 11+ years 38 21.6
Hypertension family history
 No 112 69.6
 Yes 49 30.4
Duration since diabetes diagnosis
 <5 years 29 18
 5-10 years 70 43.5
 11+ years 62 38.5
Diabetes family history
 No 53 32.9
 Yes 108 67.1
Physical activity
 None 10 6.2
 1-5 days 88 54.7
 >5 days 63 39.1
BMI
 Normal 40 24.8
 Overweight 83 51.6
 Obese 38 23.6
Low-density lipoprotein
 Normal 103 64
 High 58 36
Triglycerides
 Normal 83 51.5
 High 78 48.5
Total cholesterol levels
 Normal 102 63.2
 High 59 36.8
HBA1C
 Normal 80 49.7
 High 81 50.3
Serum creatinine
 ≤106 μmol/L 128 79.5
 >106 μmol/L 33 20.5

3.1. Social Characteristics in Association with Suboptimal Blood Pressure Control

The prevalence of suboptimal BP in this study was 57.8%. A high prevalence was obtained from male patients accounting for 60.4% and in patients aged 75 years and above (68%) (p ≤ 0.482), and retired participants had 70.8% (p ≤ 0.079) suboptimal BP control. Cigarette smoking was another factor which was associated with suboptimal BP control (as shown in Table 3).

Table 3.

Participants' sociodemographic characteristics in association with suboptimal blood pressure control (n = 161).

Variables Optimal BP Suboptimal BP Total Chi-square
N % N % p value
Age
 <50 6 50 6 50 12
 50-75 54 43.5 70 56.5 124 1.4577
 75+ 8 32 17 68 25 0.482
Sex
 Male 21 39.6 32 60.4 53 0.2212
 Female 47 43.5 61 56.5 108 0.638
Level of education
 None 1 33.3 2 66.7 3
 Primary 37 38.5 59 61.5 96 1.5960
 Secondary+ 30 48.4 32 51.6 62 0.450
Occupation
 Employed 19 51.4 18 48.6 37
 Peasant/farmer 35 46.1 41 53.9 76 5.0744
 Retired 14 29.2 34 70.8 48 0.079
Salt reduction in food
 No 17 32.7 35 67.3 52 2.8675
 Yes 51 46.8 58 53.2 109 0.090
Smoker
 No 63 42.9 84 57.1 147 0.2673
 Yes 5 35.7 9 64.3 14 0.605
Drink alcohol
 No 15 39.5 23 60.5 38 0.1556
 Yes 53 43.1 70 56.9 123 0.693

The overall suboptimal BP control according to the systolic BP (SBP) and diastolic BP (DBP) was seen in 137 (85.1%) and in 98 (60.9%), respectively. Thus, the overall suboptimal SBP/DBP was 93 (57.8%) as shown in Figure 1.

Figure 1.

Figure 1

Overall blood pressure control among the participants.

3.2. Clinical and Laboratory Characteristics of the Participants in Association with Suboptimal Blood Pressure Control

A family history of HTN of the respondents was significantly associated with suboptimal blood pressure control (71.4%) (p ≤ 0.020). Duration since the diagnosis of HTN or DM was another factor which contributed to suboptimal BP control as those who had HTN for 11 years and those who had above 5 years since DM diagnosis were 65.8% and 60%, respectively. Overweight and obesity were also associated with suboptimal BP control (56.6% and 63.2%, respectively). Suboptimal BP control was reported in 90.0% of the participants who were physically inactive, and in those who were having few days of physical activities (1-5 days per week), suboptimal BP control accounted for 59.1%. The total serum cholesterol was normal in 63.2%. Positive urine for protein was found in 21% with uncontrolled BP. Elevated serum creatinine was reported in 45.5% of the participants with suboptimal BP control whereas uncontrolled blood sugar as indicated by high HbA1C levels was recorded in 64.9% (p ≤ 0.078) of the participants. Drug adherence was another predictor of suboptimal BP control as was reported in 81.8% (p ≤ 0.004) of the participants (see Table 4).

Table 4.

Clinical and laboratory characteristics in relation to suboptimal blood pressure (n = 161).

Variables Optimal BP Suboptimal BP Total Chi-square
N % N % p value
HTN family history
 No 54 48.2 58 51.8 112 5.3909
 Yes 14 28.6 35 71.4 49 0.020
Duration of hypertension
 <5 years 28 44.4 35 55.6 63
 5-10 years 27 45 33 45 60 1.3170
 11+ years 13 34.2 25 65.8 38 0.518
Duration of diabetes
 <5 years 13 44.8 16 55.2 29
 5-10 years 28 40 42 60 70 0.2671
 11+ years 27 43.5 35 56.5 62 0.875
Physical activity
 None 1 10 9 90.0 10
 1-5 days 36 40.9 52 59.1 88 5.5775
 >5 days 31 49.2 32 50.8 63 0.061
Body mass index
 Normal 18 45 22 55 40
 Overweight 36 43.4 47 56.6 83 0.6224
 Obese 14 36.8 24 63.2 38 0.733
Low-density lipoprotein
 Normal 45 43.7 58 56.3 103 0.2475
 High 23 39.7 35 60.3 58 0.619
Triglycerides
 Normal 39 47 44 53.0 83 1.5857
 High 29 37.2 49 62.8 78 0.208
Total cholesterol levels
 Normal 46 44.2 58 55.8 104 0.4791
 High 22 38.6 35 61.4 57 0.489
HBA1C
 Normal 41 48.8 43 51.2 84 3.1108
 High 27 35.1 50 64.9 77 0.078
Drug adherence
 Never missed 37 61.7 23 38.3 60
 Missed ≤3 days 35 38.9 55 61.1 90 11.189
 Missed >3 days 2 18.2 9 81.8 11 0.004
Serum creatinine
 ≤106 μmol/L 50 39.06 78 60.9 128 2.5779
 >106 μmol/L 18 54.6 15 45.5 33 0.108

All the participants were on hypertensive treatment therapy. Renin-angiotensin system blocking drugs, i.e., angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARBs) or ACE-I/ARBs in combination with other drugs, were the most frequently prescribed antihypertensive drugs; 72.1% of the participants were on those regimens.

Significant BP control was seen in participants who were receiving ACE-I alone (63.2%); even in the multivariate logistic regression, there were no changes. The poor control of HTN was observed in patients who were on calcium channel blockers alone (88.2%) (p ≤ 0.001).

There was no big difference in suboptimal blood pressure control between patients who were taking oral hypoglycaemic drugs and those who used insulin (68.6% and 67.3%, respectively) (see Figure 2).

Figure 2.

Figure 2

The antihypertensives used in association with suboptimal blood pressure control among the participants.

The following independent variables age, sex, level of education, salt reduction, family history of HTN, and type of antihypertensive drugs showing a significant association with the dependent variable in the univariate analysis therefore were used in the multivariate analysis as shown in Table 5.

Table 5.

Determinants of suboptimal blood pressure in multivariate analysis (n = 161).

Variables Crude estimates Adjusted estimates
OR (95% CI) p values AOR (95% CI) p values
Sex
 Male Ref Ref
 Female 0.85 (0.44, 1.66) 0.638 1.07 (0.5, 2.33) 0.858
Age
 <50 Ref Ref
 50-75 1.3 (0.4, 4.24) 0.668 1.5 (0.36, 6.04) 0.588
 75+ 2.1 (0.52, 8.7) 0.295 2.53 (0.46, 13.94) 0.286
Level of education
 None Ref Ref
 Primary 0.8 (0.07, 9.1) 0.855
 Secondary+ 0.53 (.05, 6.19) 0.615 0.450
Salt reduction in food
 No Ref Ref
 Yes 0.55 (0.28, 1.1) 0.092 0.55 (0.24, 1.22) 0.142
Antihypertensive
 ACE inhibitors Ref Ref
 ARB 2.63 (1.13, 6.11) 0.025 2.27 (0.94, 5.46) 0.068
 CCB 12.86 (3.98, 41.59) <0.001 10.9 (3.29, 36.09) <0.001
 Combination therapy 2.79 (0.99, 7.82) 0.052 2.27 (0.77, 6.72) 0.139
 Other medications 2.1 (0.56, 7.57) 0.278 1.64 (0.42, 6.38) 0.475
Family history of HTN
 No Ref Ref
 Yes 2.33 (1.13, 4.79) 0.022 1.83 (0.82, 4.1) 0.142

4. Discussion

In this hospital-based cross-sectional analytical study, we explored the extent of suboptimal BP control as defined by the ADA 2018 guideline to be BP ≥ 140/90 mmHg [9].

The overall suboptimal BP control was 57.8%, whereby the prevalence of suboptimal systolic and diastolic BP control was 85% and 60.9%, respectively. This high prevalence is contributed by poor drug adherence and financial constraints for those paying out of their pockets, taking into consideration that in Tanzania, we have less than 15% of insured population. Suboptimal BP control has been reported in other many studies worldwide; to mention few, in India, uncontrolled BP was found to be 62.3% [11]; in the study done in Malaysia, suboptimal BP control was 51.75% [12]; and in the USA, 51.2% of the participants were found to have uncontrolled BP [13]. This is probably because we used the same cross-sectional methods.

The highest prevalence of suboptimal BP was observed in a study done in Singapore with 86.6% [14]. This is because it was a community-based study; i.e., there is a difference in the study population. The lowest findings were in the Netherlands with prevalence of 15% [15] and in the study done in Romania with prevalence of 10% [16]; this is because of the different methodology used in our study, they used cohort, and the retrospective nature of the study, respectively.

Suboptimal BP control was more prevalent in the elderly (56.5% and 68% among patients aged 50-75 years and above 75 years, respectively). These findings have been similar to those of other studies done in South Africa [17] and Ethiopia [18] which indicated an association of poor BP among the elderly. The explanation for this may be due to the increase in arterial stiffness and poor adherence to medication associated with advancing age, so the recommended cutoff point of BP in DM patients of <140/90 mmHg is too tight to the elderly people.

An increased body mass index as indicated by overweight and obesity was another important finding which was associated with suboptimal BP control where the prevalence was 56.6% and 63.2%, respectively. This was similar to the findings in Jordan where the prevalence of overweight and obesity was 52.5% and 28.8%, respectively [19].

Duration since the diagnosis of HTN in this study was also associated with suboptimal BP control, where 65.8% of the participants with the duration of more than 11 years were compared to those who had less duration. This was also observed in the study done in Ethiopia where the prevalence was 46.6% for participants who had duration of more than 5 years [18]. The difference is because a wide range of age categories was used. Likewise, a family history of hypertension was shown to have a strong association with suboptimal BP control by having 71.4% prevalence (p ≤ 0.02), it was different from the study done in Ethiopia which found the prevalence of 17.56% [18].

Uncontrolled blood sugar as shown by HBA1C was 68.2% which can be explained by poor adherence to medication. Elevated cholesterol was found in 50.3%; these findings are almost the same with that of the study done in Jordan (HBA1C (52.5%) and cholesterol (54.9%)) [19]. Inactivity and consumption of saturated fats in meat and cooking oils are the major factors contributing to dyslipidaemia.

Alcohol intake was another factor which contributed to suboptimal BP control among the study participants (56.9%); this is because most of the participants in our study were drinking local brew together with medication thinking that local brew was not alcohol. 87% was found in the study done in South Africa [17].

ACE inhibitors were found to be superior (53.57%) in the control of BP in diabetic patients to other antihypertensives; this has been observed in many studies including the study done in Germany which showed superiority of RAS blockade, particularly ACE inhibitors [20] and the study done in Oman that found that patients who were using ACE inhibitors (60% and 85%, respectively) had controlled pressure [21]. The use of calcium channel blockers alone was significantly associated with suboptimal BP control (88.2%). The combination of two or more drugs did not achieve treatment targets, but we still emphasize the use of more than one drug as it has been shown to have significance in various studies.

5. Conclusion

In this study, only 42.2% of hypertensive diabetic patients met the recommended BP control values in DM (<140/90 mmHg). More effort should be addressed to control the risk factors associated with poor BP control in diabetic patients. Physicians should put more emphasis on the early initiation and proper selection of antihypertensive especially the use of ACE inhibitors because they have shown better effect. It should be borne in mind that ACE-I and ARBs should not be taken concurrently.

5.1. Study Limitations

Most of the participants who attend the clinic every 2 to 3 months tend to refill their antihypertensive in other peripheral health facilities where there are limited drug options so compliance to one class or a course of antihypertensive cannot be guaranteed.

It was difficult to ascertain the contribution of dietary salt intake in the study population because we did not measure urine sodium excretion. Poor adherence to medication contributed by high cost of people who are not covered by health insurance was difficult to control.

Acknowledgments

The authors would like to convey their sincere gratitude to the management of the Kilimanjaro Christian Medical Centre (KCMC) for allowing us to conduct this study. My acknowledgment extends to members of staff of the Internal Medicine Department for their continuous support and advice, to Mr. Edwin Msheguzi for assisting in data analysis, and to all the participants for their time and willingness to participate in this study.

Abbreviations

ABCD:

Appropriate Blood Pressure Control in Diabetes

ACE-I:

Angiotensin-converting enzyme inhibitors

ADA:

American Diabetes Association

ARB:

Angiotensin II receptor blockers

BMI:

Body mass index

CVDs:

Cardiovascular diseases

DBP:

Diastolic blood pressure

DM:

Diabetes mellitus

HBA1C:

Glycosylated haemoglobin

HDL-C:

High-density lipoprotein cholesterol

HOT:

Hypertension Optimal Treatment

HTN:

Hypertension

IDF:

International Diabetes Federation

JNC 7:

Joint National Committee, seventh report

KCMC:

Kilimanjaro Christian Medical Centre

LDL-C:

Low-density lipoprotein cholesterol

NCDs:

Noncommunicable diseases

NHIF:

National Health Insurance Fund

SBP:

Systolic blood pressure

UKPDS:

United Kingdom Prospective Diabetes Study

WHO:

World Health Organization.

Data Availability

The database used during this study analysis will be available on request from the corresponding author.

Ethical Approval

This study was approved by the research ethical committee of the Kilimanjaro Christian Medical University College and was conducted with permission from the Internal Medicine Department.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors' Contributions

Gabriel W. Mbwete and Nyasatu G. Chamba were involved in the study design, study selection, data extraction, statistical analyses, and developing the initial drafts of the manuscript and preparation of the last manuscript. Elichilia Shao and Kajiru Kilonzo were involved in quality and analytical assessment of the entire study including revising the manuscript.

References

  • 1.The International Diabetes Federation (IDF) IDF Diabetes Atlas. Eighth 2017. [Google Scholar]
  • 2.Priya D., Dudhal K., Khakse G. M., Meshram R., Hiwarkar P. A., Wahab S. N. Prevalence of hypertension among type 2 diabetes patients attending diabetes clinic at tertiary care hospital, Nagpur. International Journal of Science, Environment and Technology. 2013;2(6):1401–1406. [Google Scholar]
  • 3.Rizvi A. A. Addressing hypertension in the patient with type 2 diabetes mellitus: pathogenesis, goals, and therapeutic approach. European Medical Journal. Diabetes. 2017;5(1):84–92. [PMC free article] [PubMed] [Google Scholar]
  • 4.Naccashian Z., Hattar-Pollara M., Ho C. (. A.)., Ayvazian S. P. Prevalence and predictors of diabetes mellitus and hypertension in Armenian Americans in Los Angeles. The Diabetes Educator. 2018;44(2):130–143. doi: 10.1177/0145721718759981. [DOI] [PubMed] [Google Scholar]
  • 5.Alqudah B. M., Mahmoud H., Alhusamia S., Sh A., Al L., Alawneh Z. E. Prevalence of hypertension among diabetic type 2 patients attending medical clinic at Prince Hashem Bin. Indian Journal of Medical Research and Pharmaceutical Sciences. 2017:47–54. [Google Scholar]
  • 6.Abdullah F., Han T. M., Nor M. B. M., Mohd Aznan M. A., Ismail I. Z. Prevalence of hypertension and glycaemic control in adult type-2 diabetes patients: a preliminary retrospective cohort study in Kuantan, Pahang, Malaysia. International Medical Journal Malaysia. 2017;16(1):115–121. [Google Scholar]
  • 7.Lastra G., Syed S., Kurukulasuriya L. R., Manrique C., Sowers J. R. Type 2 diabetes mellitus and hypertension: an update. Endocrinology and Metabolism Clinics of North America. 2014;43(1):103–122. doi: 10.1016/j.ecl.2013.09.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Mwita J. C., Lwakatare J., Sciences A., Chiwanga F. Hypertension control and other cardiovascular risk factors among diabetic patients at Muhimbili National Hospital, Tanzania. East African Journal of Public Health. 2012;9(2):70–73. [PubMed] [Google Scholar]
  • 9.Passarella P., Kiseleva T. A., Valeeva F. V., Gosmanov A. R. Update. 2018;2018:218–224. doi: 10.2337/ds17-0085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Menditto E., Guerriero F., Orlando V., et al. Self-assessment of adherence to medication: a case study in Campania region community-dwelling population. Journal of Aging Research. 2015:6. doi: 10.1155/2015/682503.682503 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Khrime D., Kumar A., Pandey A. N., Bansal N., Sharma U., Varma A. Antihypertensive drug utilization pattern and awareness in diabetic hypertensive patients at tertiary care centre. International Journal of Research in Medical Sciences. 2015;3(2):461–465. doi: 10.5455/2320-6012.ijrms20150215. [DOI] [Google Scholar]
  • 12.Teoh S. H., Razlina A. R., Norwati D., MY S. S. Patients' blood pressure control and doctors' adherence to hypertension clinical practice guideline in managing patients at health clinics in Kuala Muda district, Kedah. The Medical Journal of Malaysia. 2017;72(1):18–25. [PubMed] [Google Scholar]
  • 13.Mcdonald M., Hertz R. P., Unger A. N., Lustik M. B. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences. 2009;64(2):256–263. doi: 10.1093/gerona/gln016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Huang O. S., Lamoureux E. L., Tay W. T., Tai E. S., Wang J. J., Wong T. Y. Glycemic and blood pressure control in an Asian Malay population with diabetes and diabetic retinopathy. Archives of Ophthalmology. 2010;128(9):1185–1190. doi: 10.1001/archophthalmol.2010.168. [DOI] [PubMed] [Google Scholar]
  • 15.Walraven I., Mast R., Amsterdam V. U., Hoekstra T., Amsterdam V. U., Jansen A. Real-world evidence of suboptimal blood pressure control in patients with type 2 diabetes. Journal of hypertension. 2015;33(10):2091–2098. doi: 10.1097/HJH.0000000000000680. [DOI] [PubMed] [Google Scholar]
  • 16.Ciobanu D. M., Kilfiger H., Apan B., Roman G., Veresiu I. A. Resistant hypertension in type 2 diabetes: prevalence and patient characteristics. Clujul Medical. 2015;88(3) doi: 10.15386/cjmed-441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Adeniyi O. V., Yogeswaran P., Longo-Mbenza B., Goon D. Uncontrolled hypertension and its determinants in patients with concomitant type 2 diabetes mellitus (T2DM) in rural South Africa. PLoS One. 2016;11(3):1–12. doi: 10.1371/journal.pone.0150033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Muleta S., Melaku T., Chelkeba L., Assefa D. Blood pressure control and its determinants among diabetes mellitus co-morbid hypertensive patients at Jimma University medical center, South West Ethiopia. Clinical hypertension. 2017;23(1):p. 29. doi: 10.1186/s40885-017-0085-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Mohammad A., Abujbara M., Alshraideh J., Jaddou H., Ajlouni K. The Prevalence of Resistant Hypertension Among Type 2 Diabetic Patients Attending the National Center for Diabetes, Endocrinology, and Genetics. Journal of Endocrinology and Metabolism. 2017;7(5):153–158. doi: 10.14740/jem448e. [DOI] [Google Scholar]
  • 20.Ritz E. Drug of Choice in the Management of Hypertension in Diabetes and Diabetic Nephropathy: Angiotensin‐Converting Enzyme Inhibitors. The Journal of Clinical Hypertension. 2011;13(4):285–289. doi: 10.1111/j.1751-7176.2011.00448.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.El-Shafie K., Rizvi S. Control of hypertension among type II diabetics. Oman Medical Journal. 2010;25(1):32–36. doi: 10.5001/omj.2010.8. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The database used during this study analysis will be available on request from the corresponding author.


Articles from Journal of Diabetes Research are provided here courtesy of Wiley

RESOURCES